IDH1 and neoplasm: In our cases, scarce immune cells in the tumor microenvironment were observed, and Case 2 showed methylation of the MGMT promoter, which suggested the tumor-promoting effect of IDH mutation, as well as potential application of IDH-targeted therapeutics and/or methylation inhibitors, rather than immunotherapy.